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Parenteral aluminum administration in the dog: I. Plasma kinetics,
tissue levels, calcium metabolism, and parathyroid hormone. Aluminum
(Al) may cause both osteomalacia and encephalopathy in dialysis
patients. Little is known about the biology of Al. This study examined
the initial distribution kinetics of Al and its biological effects after
injections of I mg/kg/day into dogs for 3 to 5 weeks. Following one
intravenous dose, the plasma half-life (x SE) was 276 51.8 mm, with
an apparent volume of distribution of 1.30 0.17 liters or 5.90 0.30%
body wt; 10 to 21% of administered Al was excreted in the urine over
150 mm, and the renal contribution to plasma clearance of Al correlated
with GFR (r 0.77, P< 0.05). The total plasma clearance of Al (4.43
2.83 mI/mm) exceeded the renal contribution to plasma clearance (1.94
0.36 mI/mm) in each dog, and in only two instances did the renal
contribution reach 50% of total plasma clearance. Serum calcium rose
from 9.4 0.2 to 11.1 0.3 mg/dl and imniunoreactive parathyroid
hormone (iPTH) fell by 27 4% following one Al injection. With
repeated Al injections, serum calcium increased from baseline levels of
10.2 0.07 mg/dl to 11.1 0.22 and 11.3 0.46 rng/dl after 1 and 2
weeks, respectively. Renal function declined in all dogs, and serum
creatinine exceeded 3.5 mg/dl in four; over the 5 weeks of study, serum
calcium correlated with serum creatinine (r = 0.91, P < 0.001). Liver,
kidney, and spleen showed the highest tissue content of Al, and there
was substantial uptake by bone; the parathyroid content of Al was
modest. Serum iPTH levels were normal or elevated, and the response
of serum iPTH to EDTA-induced hypocalcemia was not reduced by Al
treatment. These data show substantial tissue retention of Al with
repeated Al injections. The renal excretion of Al was limited, probably
due to extensive plasma protein and tissue binding. Parenteral Al
caused marked disturbances in calcium metabolism and renal function,
but the PTH response to hypocalcemia was not impaired.
Administration parentérale d'aluminium chez le chien: I. Cinetique
plasmatique, niveaux tissulaires, le métabolisme calcique, et l'hormone
parathyroidienne. L'aluminium (Al) peut entrainer une ostéomalacie et
une encephalopathie chez des hemodialysés. On salt peu de choses sur
Ia biologie de l'Al. Cette étude a examine Ia cinétique de distribution
initiale de l'Al et ses effets biologiques après des injections de I
mg/kg/jour a des chiens pendant 3 a 5 semaines.AprCs une dose
intraveineuse, Ia demi-vie plasmatique (x SE) était 276 51,8 mm,
avec un volume de distribution apparent de 1.30 0.17 litres ou 5.90
Received for publication January 14, 1983
and in revised form June 8, 1983
© 1984 by the International Society of Nephrology
0.30% do poids corporel; 10 a 21% de l'Al administré était excrété dans
les urines en 150 mm, et Ia contribution rénale a l'epuration plasmatique
de l'Al était corrélée avec le debit de filtration glomerulaire (r = 0,77, P
< 0,05). La clearance plasmatique totale de l'Al (4,43 2,83 mI/mm)
dépassait Ia contribution rénale ala clearance plasmatique (1,94 0,36
mi/mm) chez chaque chien, et seulement deux fois Ia contribution
rénale a atteint 50% de Ia clearance plasmatique totale. La calcémie
s'est élevée de 9,4 0,2 a 11,1 0,3 mg/dI et l'hormone parathyroi-
dienne immunoréactive (iPTH) a chute de 27 4% apres une injection
d'Al. Lors d'injections répétées d'Al, Ia calcCmie s'est élevée du niveau
debase de 10,2 0,07 mgldl a 11,1 0,22 et 11,3 0,46 mg/dl après I
et 2 semaines, respectivement. La fonction rénale a diminué chez tous
les chiens, et Ia créatinine sérique a dépassé 3,5 mg/dl chez quatre; au
cours des 5 semaines de l'étude, Ia calcémie Ctait corrélée avec Ia
créatininémie (r = 0,91, P <0.001). Le foie, le rein, et Ia rate avaient le
plus grand contenu tissulaire en Al, et il y avait une fixation substan-
tielle dans l'os; le contenu parathyroidien en Al était modeste. Les
niveaux d'iPTH sérique étaient normaux ou élevés, et Ia rCponse de
l'iPTH a une hypocalcémie induite par 1'EDTA n'était pas réduite par le
traitement a I'Al. Ces données indiquent une retention tissulaire sub-
stantielle d'Al aprés injections répétées d'Al, L'excrétiori rénale d'Al
était limitée, probablement a cause d'une liaison importante aux
protéines plasmatiques et aux tissus. L'Al parentéral a entrainé des
perturbations marquees du métabolisme calcique et de Ia fonction
rénale, mais Ia réponse de Ia PTH a l'hypocalcémie n'Ctait pas altérée.
Aluminum has received considerable attention as a pathogen-
ic factor in both dialysis dementia and osteomalacia [1—12]. The
data in support of the association between aluminum accumula-
tion and osteomalacia are particularly convincing. Thus, clini-
cal studies of renal osteodystrophy indicate an association
between bone aluminum content and both the frequency and
severity of vitamin D-resistant osteomalacia in patients under-
going hemodialysis [8, 10, 11]. Ellis, McCarthy, and Herrington
[13] showed that injections of aluminum to rats impaired the
mineralization of the tibial metaphysis. In addition, the inadver-
tent administration of aluminum to patients treated with long-
term total parenteral nutrition has been associated with the
development of focal osteomalacia [14—161.
Despite the potential toxic manifestations of aluminum accu-
mulation, little is known regarding the kinetics of aluminum
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distribution after its parenteral administration or its biological
effects in humans or experimental animals. Aifrey, Hegg, and
Craswell [17] demonstrated substantial accumulation of alumi-
num in tissues, particularly bone and liver, from uremic pa-
tients, whether treated with dialysis or not. Other investigators
[18] found accumulation of aluminum in the parathyroid glands;
moreover, the addition of aluminum to suspensions of parathy-
roid cells, in vitro, inhibits the secretion of PTH [19]. These
latter observations may pertain to the syndrome of dialysis
osteomalacia, which is characterized by altered calcium-PTH
relationships [17]. Thus, these patients often show a propensity
to hypercalcemia, and serum iPTH levels are often lower than
predicted in the face of renal insufficiency [12, 20—221.
Most observations have suggested that plasma aluminum is
largely protein-bound and not readily removed by hemodialysis
techniques [23, 24]. Thus, since the renal excretion of aluminum
represents the predominant route for its elimination [23], alumi-
num accumulation is particularly likely to occur in the presence
of renal insufficiency [17].
The present studies were conducted to investigate the kinet-
ics of aluminum following its injection into dogs. Also, the
biological consequences of both single and repeated injections
of aluminum were studied, as was its tissue distribution. The
response of serum immunoreactive parathyroid hormone
(iPTH) to acute hypocalcemia induced by sodium-EDTA was
also evaluated before and after aluminum loading.
Methods
Studies were carried out in six normal, female mongrel dogs,
weighing 18 to 34 kg. Prior to study, the animals had undergone
episiotomy for ease of bladder catheterization. The animals
were studied during a 14-day control period prior to aluminum
injections, and for 3 to 5 weeks while they received daily
aluminum injections. Fasting blood samples were obtained
twice weekly for the measurement of calcium, phosphorus,
creatinine, and aluminum concentrations.
Renal function was evaluated initially by exogenous creati-
nine clearances and subsequently from serial serum creatinine
levels. Basal serum iPTH levels were measured biweekly, and
the secretory response to acute hypocalcemia was studied
during the control period and after 10 and 20 days of aluminum
injections.
The kinetics of aluminum disappearance from plasma were
examined after its initial bolus injection and again in two dogs
after 3 weeks of aluminum administration. Continued aluminum
loading was produced by giving daily bolus injections of alumi-
num chloride, each providing elemental aluminum, 1 mg/kg, on
5 days each week for 3 to 5 weeks. Aluminum chloride was
dissolved in 0.85% saline and infused intravenously in a volume
of 8 to 15 ml over 45 to 60 sec on 5 mornings each week. This
solution had a relatively low pH of 2,6, but the total acid load
provided to each dog was only 0.10 mEq/kg/day. This small
quantity of acid represents only a small fraction of the usual
endogenous acid production of 3 mEq/kg/day in the dog [25].
The plasma clearance studies were conducted with the dogs
in the unanesthetized, fasting state while supported in the
standing position by a sling-harness. The animals were prepared
for these clearance studies by cannulation of two separate
superficial limb veins, one of which was used for the adminis-
tration of parenteral fluids and the other for obtaining blood
specimens. An indwelling balloon catheter was inserted in the
bladder for urine collections. A water diuresis was initiated by
the administration of 40 ml/kg of water by a nasogastric tube
followed by the infusion of 2.5% dextrose in water at 4 mI/mm.
Exogenous creatinine clearances were carried out after an
initial loading dose of 8% creatinine (60 mg/kg) followed by a
constant infusion of 1% creatinine at a rate of 1 mI/mm. After a
stable urine flow rate was established, that is, above 50 mi/iS
mm, the aluminum kinetic studies were carried out. Individual
urine collections, of 15 mm duration, were obtained for 30 mm
before and 150 mm after the aluminum injection; blood samples
were collected precisely at the midpoint of each collection
period. In one animal, ultrafiltrates of plasma were prepared
both in vivo during a hemodialysis procedure by isolated
ultrafiltration using a cuprophan membrane and also in vitro by
the centrifugation of plasma through a membrane (Centriflow,
Amicon, Lexington, Massachusetts) at 2000 rpm at 21°C for 30
mm; the fraction of aluminum that was ultrafilterable in vivo
was 3.9%; 2.5% was diffusable during centrifugation. Ultrafil-
terabie levels of aluminum were not measured during the
present clearance experiments, but diffusable aluminum levels
were determined in 15 samples from five other dogs given a
comparable aluminum load; the percentage diffusability was
2.82 0.51%. During the present experiments, the renal
contribution to plasma clearance was calculated based on total
plasma aluminum. Also, the renal clearance of aluminum, as
calculated, does not have the same meaning regarding renal
handling as the usual renal clearance because of our lack of
information regarding the quantity of aluminum that was actual-
ly filtered.
In all dogs, the response of the parathyroid glands to hypocal-
cemia induced by the infusion of sodium EDTA was assessed 3
days before initiation of aluminum injections and again after
week 2 of aluminum injections; in two dogs, the sodium EDTA
infusion was repeated at the end of 4 weeks. For the studies
done after initiation of aluminum administration, the sodium
EDTA infusions were given 24 hr after the previous daily
injection of aluminum. In all studies, sodium-EDTA (75 mg/kg
body wt) was infused at a constant rate over 2 hr. Blood
samples were obtained for the determination of ionized calcium
and iPTH before the infusion of sodium EDTA, at 30-mm
intervals during the EDTA infusion, and for 2 hr thereafter.
The experiments were terminated after 3 to 5 weeks of
aluminum loading. In two dogs, the studies were terminated
after 3 weeks because of the rapid appearance of renal insuffi-
ciency (see Results). When the studies were terminated, the
animals were killed with pentobarbitol, 40 mg/kg. Samples of
bone, liver, kidney, thyroid, spleen, parathyroid, muscle, and
brain were obtained for the measurement of aluminum content.
Renal histology was evaluated in all animals except dogs 1 and
2. Tissue samples were fixed in neutral formalin and then
embedded in paraffin. Sections were stained with hematoxylin
and eosin, and periodic acid-Schiff; the von Kossa stain for
calcium and the Gram stain (Brown and Prenn technique) were
also done.
Total calcium concentrations were determined in serum and
urine by atomic absorption spectroscopy, as reported else-
where [22], ionized calcium in serum by the flow-through
electrode (Orion Biomedical, Cambridge, Massachusetts),
phosphorus and creatinine using an autoanalyzer (Technicon
Instruments Corporation, Tarrytown, New York). Aluminum
was determined in serum, urine, and tissue samples by flame-
less atomic absorption spectroscopy [26]. Serum IPTH was
determined by radioimmunoassay utilizing an antibody (Ch 9)
which is directed against the mid-region of the carboxyl termi-
nus of the PTH molecule [27]. The levels of iPTH, measured in
dogs with moderate reductions in renal function, have been
shown to correlate with histologic evidence of secondary hyper-
parathyroidism [28].
All values are expressed as the mean SE; statistical analysis
of the data utilized Student's t test for paired samples and linear
regression analysis.
Results
Single dose aluminum administration
Following the first intravenous dose of aluminum (1 mg/kg),
the mean plasma aluminum concentration reached 17,835
1,294 and 16,069 1,295 g/1iter at 7.5 and 22.5 mm, respec-
tively. The plasma levels then decreased slowly and followed a
pattern over 150 mm which was consistent with first-order
kinetics for the disappearance of aluminum from plasma; an
example is shown in Figure 1. The values for apparent volume
of distribution (Vd), plasma half-life, and both the total plasma
clearance and the renal contribution to the plasma clearance of
aluminum for individual dogs are shown in Table 1. The mean
plasma half-life, derived from the elimination curves for each of
the six dogs was 276 52.8 mm. The Vd was 1.30 0.17 liters
or 5.90 0.30% of body wt, representing values nearly twice
the estimated plasma volume in these individual animals. From
the subsequent tissue distribution of aluminum (described be-
low), it is apparent that the volume of distribution was consider-
ably larger; however, the entry of aluminum into the tissues
may have occurred so slowly that it was not apparent over the
150 mm of this study.
The mean renal contribution to the clearance of aluminum
from plasma was 1.94 0.36 mI/mm, with 10 to 21% of the total
aluminum load excreted in the urine over 150 mm. The total
clearance of aluminum from plasma was 4.43 0.83 mI/mm. On
the average, the kidney accounted for 44% of plasma aluminum
removal and in only two dogs did this value exceed 50%. The
renal contribution to plasma clearance of aluminum, measured
after the initial injection, was related directly to GFR (r = 0.77,
P < 0.05).
A prompt and sustained increase in serum calcium concentra-
tion followed the initial injection of aluminum chloride in each
dog (Fig. 2) which was accompanied by small but significant
increments in urinary calcium excretion. There was a modest
increase in serum phosphorus concentration which was signifi-
cant only at 30 mm following the aluminum injection (4.5 0.6
to 5.6 0.7 mg/dl). In each dog, the serum iPTH level fell after
the aluminum injection (Fig. 3), with an average decrease of 27
4%.
Effects of repeated aluminum injections
The continued injection of aluminum for 5 days each week for
3 to 5 weeks led to disturbances of calcium homeostasis and
renal function. By the end of week 1, total serum calcium
concentrations measured before the daily aluminum injection
increased in five of the six dogs; the mean values increased
from a baseline of 10.16 0.07 mg/dlto 11.05 0.22 and 11.33
0.46 mg/dl at the end of weeks 1 and 2, respectively (Fig. 4).
Near the time for the studies to end, the total serum calcium
concentration increased markedly in three of the dogs.
Renal function, evaluated from serial serum creatinine levels
and exogenous creatinine clearances, decreased in all dogs (Fig.
5). In four of six animals, serum creatinine levels exceeded 3.5
mg/dl at the completion of these studies; however, the marked
increments in serum creatinine occurred only at the termination
of the study in three of the animals. The rise in serum creatinine
closely paralleled the increments in serum calcium, with a
significant correlation between serum calcium and serum creati-
nine concentrations over the course of the experiments (r =
0.91, P < 0.001). Despite these changes in serum calcium and
creatinine, the body weight of the dogs remained within 0.5 kg,
with the exception of one dog that had a weight loss of 2 kg.
At the end of weeks 1 and 4 of aluminum injections, the basal
morning plasma aluminum levels, which were measured 24 hr
following the previous injection were related inversely to both
the renal and total clearances of aluminum from plasma (Fig. 6),
which had been measured 4 days earlier. The basal plasma
aluminum levels, obtained prior to the daily injection of alumi-
num and shown in Figure 7, remained relatively stable although
there was substantial variation from dog to dog. Liver, kidney,
and spleen tissues had the greatest accumulation of aluminum at
the time the experiments were completed (Table 2). There was
also a substantial uptake of aluminum into bone. The results of
quantitative histomorphometry of trabecular bone and the
relationship between aluminum administration and the develop-
ment of osteomalacia in these animals are reported elsewhere
[29]. Three of the four dogs that exhibited a marked impairment
of renal function demonstrated the highest levels of aluminum
in renal tissue (> 1000 mg/kg).
The histopathology of the kidneys at the conclusion of the
studies revealed variable changes that were not seen uniformly
in all animals. Thus, focal tubular necrosis was present only in
dog 6; focal infiltrates with acute inflammatory cells occurred in
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Fig. 1. Example of the disappearance curve of aluminum after its
injection (1 mg/kg elemental Al) in dog no. 1. The initial blood sample
was obtained 7.5 mm after the injection with subsequent samples at 15-
mm intervals. PC Al represents the plasma clearance of aluminum.
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Table 1. Analysis of plasma kinetics in individual dogs following the injection of aluminuma
.
.
Plasma clearanc&'
Dog
no.
GFR
mi/mm
Volume of distribution
—
Total
liters % body wt
Plasma t 1/2
mm
Urine
Al
% dose in 150 mm
Total Renal
mi/mm
1 67.3 1.32 4.7 198 9.6 4.63 1.09
2 55.7 1.63 5.7 470 15.0 2.48 1.76
3 72.4 2.21 6.3 317 18.4 4.82 3.20
4 59.7 1.38 6.3 295 13.0 3.24 1.54
5 54.1 1.36 6.8 287 11.4 3.28 1.24
6 86.2 1.03 5.7 88 21.3 8.15 2.83
5c 31.3 1.44 7.2 95 — 10.5 4.19
6' 43.8 1.47 7.9 88 — 11.6 7.23
Mean 65.9 1.30 5.95 276 14.8 4.43 1.94
±SE ±5.0 ±0.17 ±0.30 ±52.8 ±1.8 ±0.83 ±0.36
a Means ± SE are limited to initial studies carried out in the six dogs.
b See Results for discussion of renal contribution to plasma aluminum clearance.
Studies in these animals were repeated after 3 weeks.
j
30 60 90 120 150
Fig. 2. The changes in serum calcium, phosphorous, and urinary
calcium excretion in dogs after the initial injection of aluminum, I
mg/kg. Values are mean ±SE. The asterisk (*) indicates values that
differ significantly from control values, by paired analysis P < 0.05.
dogs 3, 4, and 5, and scattered areas of degenerated tubules
were present in dogs 3 and 6. There were small focal areas of
calcium deposition only in dog 3. Of particular interest was the
minimal nature of calcium deposition in the renal parenchema,
in view of the hypercalcemia that developed in this animal.
The serial values of serum iPTH are shown in Figure 8. Four
of the six dogs, those with the greatest increments in serum
creatinine, showed a rise in serum iPTH to values above normal
for this assay in the dog. During the overall period of study
Time, mm
Fig. 3. Serum iPTH levels before and 150 mm after the initial injection
of aluminum, 1 mg/kg. The fall in serum iPTH was significant, P < 0.05.
The following symbols represent individual dogs by number: I, •; 2, 0;
3, X; 4, ; 5, A; 6, LII.
there was a significant correlation between serum iPTH and
serum creatinine (r = 0.51, P < 0.01).
The changes in serum iPTH in response to EDTA-induced
hypocalcemia prior to and following the parenteral aluminum
loading are shown in Figure 9. Following the infusions of
EDTA, serum ionized calcium decreased from 4.87 ± 0.056 to
3.68 ± 0.25 mgldl during the control study before aluminum
administration and from 5.04 ± 0.20 to 3.47 ± 0.20 mgldl after
10 days of aluminum treatment. Aluminum administration did
not cause a significant decrease in either the control, pre-EDTA
serum levels of ionized calcium, or the percent decrement in
ionized calcium produced by the sodium-EDTA. With these
similar decrements of ionized serum calcium, the peak serum
iPTH levels, expressed as a percent of the control value
obtained prior to the EDTA infusion, were not different before
or after aluminum loading. There was no evidence that the
E
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infusion of sodium EDTA on days 10 and 20 had any effect on
the basal levels of either serum calcium or aluminum, as
determined by biweekly measurements.
Discussion
Considerable evidence indicates that aluminum may be
pathogenic in both dialysis dementia and dialysis-associated
osteomalacia. Aifrey, Hegg, and Craswell [17] demonstrated
substantial tissue retention of aluminum in patients with renal
insufficiency, regardless of whether or not long-term dialysis
had been used in their treatment regimen. The results of the
present study not only support the earlier findings which show
tissue accumulation of aluminum but also provide additional
insight into the kinetics of aluminum in plasma and its renal
excretion. The results obtained following both acute single
injections and short-term aluminum loading indicate that renal
excretion contributes substantially to the total plasma clearance
of aluminum. In contrast to previous studies [23], the clearance
of aluminum from plasma by the kidney was quite low in the
present experiments. Only 10 to 20% of injected aluminum was
excreted in the urine over 150 mm. This finding, the very high
plasma aluminum levels achieved after the bolits injection, the
small calculated initial volume of distribution of aluminum, and
the measurement of ultrafilterable aluminum in one animal
suggest that a large fraction of administered aluminum is
promptly bound to plasma proteins. The conclusion that little of
the plasma aluminum is ultrafilterable is supported by work
demonstrating very limited plasma clearances of aluminum
across hemodialysis membranes [24] and by observations in
patients treated with long-term total parenteral nutrition [16].
The present observations provide strong support for the view
that there is slow, progressive accumulation of administered
aluminum in tissues. The plasma kinetic data show that the
renal contribution to aluminum clearance accounts for less than
half of its disappearance from plasma. Data reported elsewhere
[16, 23] indicate that there is little gastrointestinal excretion of
aluminum that has been given parenterally. Thus, the extra-
renal clearance of aluminum may be accounted for, in large
part, by the slow continued uptake of aluminum into tissues.
Since aluminum can accumulate in the body's with repeated
exposure and since there is a limited capacity for the kidney to
excrete aluminum, it can be anticipated that a considerable
interval without aluminum exposure may be needed for the
kidney to reduce the body's burden of aluminum significantly.
This contention is supported by clinical studies which show that
the urinary excretion of aluminum by renal transplant recipients
may be increased for up to 6 months following renal transplan-
tation [30].
The disturbances in calcium homeostasis and renal function
observed in the present study were unexpected. Moderate
hypercalcemia developed within minutes after single bolus
injections of aluminum, whereas repeated aluminum injections
produced hypercalcemia that was sustained for several weeks.
Factitious hypercalcemia was excluded as an explanation for
these findings; thus, the addition of aluminum to plasma did not
interfere with serum calcium determinations as measured by
atomic absorption spectroscopy over a wide range of plasma
aluminum concentrations. Unfortunately, serum ionized calci-
um levels were not measured throughout the experiment. When
ionized calcium levels were measured after 10 and 20 days,
respectively, of aluminum administration, they had not in-
creased significantly despite the mean increase in total serum
calcium of 1.1 mg/dl and the highest total serum calcium of 12.7
mgldl. The lack of long-term suppression of serum iPTH levels
suggests that serum ionized calcium was not increased, al-
though no conclusion can be reached in the three animals that
developed marked hypercalcemia just before the studies were
completed. The modest decrease in serum iPTH levels ob-
served during the initial infusion of aluminum suggests that
serum ionized calcium may have increased transiently during
the time of this acute study. Further investigation is needed to
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Fig. 5. Serial levels of serum creatinine in dogs receiving repeaten
aluminum loading as in Figure 4 (note log scale of serum creatinine).
The symbols are the same as those used in Figure 3.Fig. 4. Serial levels of total serum calcium following repeated aluminum
injections, 1 mg/kg, given intravenously on 5 days of each week. Lines
connect the values obtained in the same animal. The symbols are the
same as those used in Figure 3.
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Fig. 6. The relationship between morning, basal plasma aluminum
levels, and both the renal contribution to plasma clearance (top panel)
and the total plasma clearances (bottom panel) of aluminum. These
clearance measurements were determined after the intravenous infu-
sion of a single dose of aluminum, 1 mg/kg (see Table I); the basal
serum aluminum level was measured 4 days later, 24 hr after the
previous injection of aluminum. Renal clearance calculations utilized
total serum aluminum measurements (see Results).
clarify the effects of aluminum on the partition of calcium in
plasma.
Overt hypercalcemia or a predisposition to its development
with either calcium or vitamin D therapy has occurred in
patients with the syndrome of dialysis osteomalacia that is
associated with aluminum accumulation in bone [10, 12]. The
present data suggest that this tendency toward hypercalcemia
could represent a direct effect of aluminum, per se.
Despite our lack of definitive data regarding changes in the
distribution of calcium within its various components in plasma,
the present observations do permit speculation regarding the
mechanisms of calcium transfer or flux during the administra-
tion of aluminum. With a single bolus injection of aluminum, the
rise in total serum calcium level was prompt and sustained
without evidence for excessive PTH secretion. The time course
of this change is too brief to incriminate an intestinal mecha-
nism for the development of hypercalcemia, and the increase in
urinary calcium excretion excludes a renal mechanism. Thus, it
Fig. 7. Serial values of plasma aluminum before and during the
repeated loading with aluminum; the latter measurements were made
at least 24 hr after the previous injection of aluminum. Symbols
represent individual dogs and are the same as those used in Figure 3.
is most likely that serum calcium levels increased acutely due to
the mobilization of skeletal calcium arising as a consequence of
the aluminum injection. The precise mechanism of this re-
sponse remains uncertain.
With repeated injections of aluminum, hypercalcemia be-
came sustained and progressive; indeed, it was very marked in
some animals. It is likely that pathophysiologic mechanisms
other than calcium release from bone contributed to the striking
increase in total serum calcium. As serum calcium and its
filtered load increase, the renal excretion of calcium represents
an important mechanism for protection against worsening hy-
percalcemia [31]. With the continued entry of calcium into the
extracellular fluid, hypercalcemia might be aggravated if renal
function is significantly reduced. Under these conditions, the
entry of calcium into the skeleton may be critical in the defense
against further increments in serum calcium. With the repeated
injections of aluminum into these dogs, there was a close
correlation between the total serum calcium concentration and
the serum creatinine level; moreover, marked hypercalcemia
(serum calcium levels above 15 mg/dl) developed only in the
face of an abrupt and striking reduction in renal function noted
late in the course of the study. This degree of hypercalcemia
cannot be explained only on the basis of reduced renal function;
the calcium entering the extracellular fluid probably originated
from the skeleton as an example of "disequilibrium hypercalce-
mia" which was aggravated by renal failure [31, 32]. Other
factors could also contribute to the hypercalcemia in the
present studies. Although it is possible that intestinal calcium
absorption could have been increased, this seems unlikely in
the face of the reduced serum levels of 1 ,25(OH)2D observed
[291. Moreover, there were variable reductions in food intake in
some of the dogs.
The present data do not permit delineation of the relative
contributions of excessive calcium mobilization versus reduced
calcium uptake by bone to the pathogenesis of hypercalcemia.
Bone biopsy specimens following aluminum administration
showed evidence of osteomalacia with reduced rates of bone
apposition and poor uptake of tetracycline into bone [29]. These
findings would clearly indicate reduced entry of calcium into
bone. On the other hand, the severity of the hypercalcemia
makes it unlikely that serum calcium increased entirely as a
consequence of reduced calcium entry into bone. Calcium
.
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Table 2. Tissue levels of aluminum in dogs receiving repeated aluminum injections
Tissue aluminum, mg/kg/FFDW
Bone'
Dog
.Brain
no. Liver Kidney Muscle Thyroid Parathyroid Spleen g Pre Post
lb 330 1234 3.0 58.0 31.0 — 5.2 ND 91
2b 462 1089 4.5 — 79.0 — 7.2 1.2 136
3 563 275 20.0 23.0 48.0 594 11.2 ND 129
4 440 1512 2.5 13.5 40.0 581 2.8 1.5 94
5 334 209 3.5 6.2 16.0 559 3.8 1.0 78
6 231 104 2.5 8.7 19.0 440 3.4 4.3 90
Mean 393 737 6.0 21.9 38.8 554 5.6 1.5 103
±SE ±48 ±249 ±2.8 ±9.5 ±9.4 ±35 ±1.3 ±0.58 ±9.6
Abbreviations: ND, not detectable (<0.5 mg/kg); FFDW, fat free dry weight.
a Pre and Post refer to aluminum administration.
This animal received aluminum loading for 3 weeks; other animals received aluminum for 5 weeks.
Time, days
Fig. 8. Serial values of serum immunoreactive parathyroid hormone(iPTH), measured with a carboxyl terminal antiserum, during the
repeated loading with aluminum as described in Figure 4.
Fig. 9. The maximum increment in serum iPTH, represented as a
percent of the control value, after hypocalcemia induced with sodium-
EDTA, 75mg/kg. Studies were before (control) and after 10 days of the
repeated aluminum injections. In two dogs (*) the response was
evaluated on a second occasion after 4 weeks of aluminum loading.
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could be liberated into the extracellular fluid as a consequence
of increased bone resorption, although the data supporting this
mechanism in the current study are only indirect. In an exten-
sion of the present studies [29], there was a reduction in
trabecular bone volume without an increase in resorptive
surface of bone, suggesting that bone resorption may not have
occurred through normal bone remodeling processes. Howev-
er, this calcium mobilization might also involve a more rapidly
exchangeable pool of calcium in bone. There are no data
available to distinguish between these possibilities, although
preliminary evidence suggests that aluminum loading may in-
crease resorptive activity in the tibial diaphysis of the rat [331.
Anotherfeature of the clinical syndrome of dialysis osteoma-
lacia is the presence of serum iPTH levels which are lower than
expected in advanced renal failure [10]. Moreover, there are
data suggesting that aluminum may accumulate preferentially in
the parathyroid glands [18], and other observations indicate that
aluminum can reduce PTH secretion by parathyroid cells
studied in vitro [19]. Thus, it is possible that aluminum may
have a direct inhibitory effect on the parathyroid glands. The
results of the present investigation neither demonstrate marked
aluminum accumulation by parathyroid tissue compared to
other types of tissue nor do they indicate that aluminum
produced a defect in the secretory reserve for PTH in response
to acute hypocalcemia. However, the present studies were
conducted after the administration of aluminum for relatively
short periods. Therefore, an effect of more prolonged aluminum
loading on PTH secretion cannot be excluded. Indeed, the
present results do not exclude the possibility that a reduction in
parathyroid activity may in some way predispose to the accu-
mulation of aluminum in bone and the occurrence of the
syndrome of dialysis osteomalacia.
The dose of aluminum given to these animals was high;
however, on a body weight basis, it was generally far less than
that given to rats [13, 34, 351. Thus, the serum aluminum levels
measured were substantially greater than those observed in
clinical conditions of aluminum loading. However, the tissue
Kinetics of aluminum in the dog 369
levels achieved, particularly those in bone, were comparable to
those observed in clinical conditions associated with exposure
to aluminum [10, 17, 161.
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